Inspire Investing LLC Has $407,000 Holdings in Biohaven Ltd. (NYSE:BHVN)

Inspire Investing LLC lifted its position in Biohaven Ltd. (NYSE:BHVN) by 32.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,895 shares of the company’s stock after purchasing an additional 2,698 shares during the quarter. Inspire Investing LLC’s holdings in Biohaven were worth $407,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in shares of Biohaven in the 3rd quarter valued at $50,000. Values First Advisors Inc. acquired a new position in Biohaven in the third quarter worth about $78,000. US Bancorp DE lifted its stake in Biohaven by 57.1% during the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock worth $109,000 after purchasing an additional 790 shares during the period. KBC Group NV boosted its holdings in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after purchasing an additional 443 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its stake in shares of Biohaven by 19.1% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock valued at $156,000 after purchasing an additional 500 shares during the period. 88.78% of the stock is owned by institutional investors.

Biohaven Stock Performance

NYSE BHVN opened at $39.36 on Friday. The stock has a market capitalization of $3.98 billion, a P/E ratio of -4.21 and a beta of 1.29. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The stock has a fifty day moving average of $40.37 and a 200-day moving average of $42.49.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). Equities research analysts forecast that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director John W. Childs acquired 29,000 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. This trade represents a 1.24 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 16.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on BHVN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price target (up previously from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. HC Wainwright reaffirmed a “buy” rating and issued a $59.00 target price on shares of Biohaven in a report on Tuesday, December 17th. JPMorgan Chase & Co. lifted their price target on shares of Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, October 3rd. Finally, TD Cowen upped their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Thirteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $63.00.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.